These observations align with clinical studies associating high densities of CD20+ B cells in sentinel LNs (including tumor-free nodes) with improved disease-free survival across TNBC, basal-like, and HER2-enriched breast cancer subtypes (53–58). This evidence concerns the gene ERBB2 and neoplasm.